|
Brian Murphy was most recently Chief Medical Officer at Valeant Pharmaceuticals International where he oversaw development portfolios in neurology and hepatology, including the taribavirin, Pradefovir and Infergen programs. Prior to joining Valeant, Dr. Murphy held a number of management posts at InterMune, Inc., including Vice President of Hepatology Marketing, and served as Medical Director of North America for Hoffmann-LaRoche working on the development of Pegasys for the treatment of chronic hepatitis C. Dr. Murphy earned his medical degree, master of science in pharmacology, and master of public health degrees from New York Medical College and went on to complete his master of public health in health care policy and management at Harvard University. Dr. Murphy is board-certified in internal medicine, having completed his residency and chief residency in internal medicine at Tufts-New England Medical Center in Boston. He went on to complete fellowships in Clinical Medicine & Epidemiology at Massachusetts General Hospital-Harvard Medical School and in medical ethics at Harvard Medical School where his research interests focused on issues of distributive justice in health care. Dr. Murphy�s clinical practice was focused on the treatment of HIV and HCV and examining clinical outcomes and therapies for those diseases. While serving as Director of Clinical Strategies for the Catholic Healthcare Network of New York, Dr. Murphy earned his MBA from Columbia University. He serves as a reviewer for a variety of professional publications, including the Annals of Internal Medicine. | 